Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03564119 · ClinicalTrials.gov registry record · Phase 3
A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea
A Phase 3 study, sponsored by Sol-Gel Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 372
- Enrollment target
NCT03564119 is a Phase 3 study that has completed, run by Sol-Gel Technologies. The registered enrollment target is 372 participants.
The verdict
NCT03564119, a Phase 3 study, has completed, sponsored by Sol-Gel Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 372 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
Interventions
- DRUG S5G4T-1
- DRUG S5G4T-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03564119
The ClinicalTrials.gov registry entry for NCT03564119 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 372 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sol-Gel Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which S5G4T-1 is the first listed.
NCT03564119 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03564119 about?
NCT03564119 is a clinical study titled "A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea". To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
What is the current status of trial NCT03564119?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 372 participants. The study started on 2018-06-21. Estimated completion is 2019-06-10.
What interventions are being tested in trial NCT03564119?
The interventions under investigation include: S5G4T-1 (DRUG), S5G4T-2 (DRUG).
Who is sponsoring clinical trial NCT03564119?
This trial is sponsored by Sol-Gel Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.